Lobbying Filing Details
Total Spending
$60,000
Activities
3
Lobbyists
3
Gov't Entities
6
Filing Information
- Filing UUID:
d7fb34fe-9f1f-4f43-bf8a-6ed787a9dab9- Type:
- Q2 - 2nd Quarter - Report
- Period:
- 2026 - 2nd Quarter (Apr 1 - June 30)
- Date Posted:
- July 20, 2026 at 7:57 PM
- Income:
- $60,000
- Expenses:
- $0
- Document URL:
- View Submission
Quick Info
- Document Type: text/html
- Posted By: Alisa Hess
Registrant
ALPINE GROUP PARTNERS, LLC.
Public relations consulting firm
Washington, District of ColumbiaClient
ULTRAGENYX PHARMACEUTICAL INC.
Biopharma company developing treatments for rare and ultra-rare diseases.
California, United States of AmericaLobbying Activities (3)
Activity 1
Government IssuesMonitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases like Sanfilippo syndrome Type A, Duchenne Muscular Dystrophy (DMD), and Metachromatic Leukodystrophy (MLD)
Lobbyists (3)
- KEENAN AUSTIN REED
- SHAYNE WOODS
- ERIN MENDELSOHN
Government Entities (2)
- SENATE
- HOUSE OF REPRESENTATIVES
Activity 2
Health IssuesMonitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases like Sanfilippo syndrome Type A, Duchenne Muscular Dystrophy (DMD), and Metachromatic Leukodystrophy (MLD)
Lobbyists (3)
- KEENAN AUSTIN REED
- SHAYNE WOODS
- ERIN MENDELSOHN
Government Entities (2)
- SENATE
- HOUSE OF REPRESENTATIVES
Activity 3
Medical/Disease Research/Clinical LabsMonitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases like Sanfilippo syndrome Type A, Duchenne Muscular Dystrophy (DMD), and Metachromatic Leukodystrophy (MLD)
Lobbyists (3)
- KEENAN AUSTIN REED
- SHAYNE WOODS
- ERIN MENDELSOHN
Government Entities (2)
- SENATE
- HOUSE OF REPRESENTATIVES